GlassScriptPhysician profile
Rani Kaur Singh
NPI 1982850418
$6,767.67
in general payments reported to CMS, 2019-2025
13 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.70 · 2021: $1,595 · 2022: $1,550 · 2023: $2,982 · 2024: $283 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,020 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $650 · Food and Beverage: $502 · Honoraria: $300 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,020.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $650.00 |
| Food and Beverage | $502.12 |
| Honoraria | $300.00 |
| Education | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $1,740.00 | 2022-2023 | Spritam |
| Immedica Pharma US, INC. | $1,714.44 | 2022-2023 | |
| Zogenix INC. | $1,550.00 | 2021 | |
| Livanova USA, INC. | $475.30 | 2023 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Owp Pharmaceuticals, INC. | $300.00 | 2023 | Lamotrigine, Subvenite |
| Sk Life Science, INC. | $252.80 | 2023-2025 | Xcopri |
| Acadia Pharmaceuticals INC | $226.23 | 2023-2024 | Daybue |
| Jazz Pharmaceuticals INC. | $208.09 | 2022-2025 | |
| Ucb, INC. | $134.44 | 2021-2025 | Nayzilam, Briviact, Fintepla |
| Neurelis, INC. | $91.48 | 2025 | Valtoco |
| Greenwich Biosciences, INC. | $39.74 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $35.15 | 2023 | Oxtellar Xr |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rani Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.